Aided by Clean FDA Label, US Dermatologists Report BMS' Sotyktu Has Potential to Delay Biologic Treatment in Plaque Psoriasis, According to Spherix Global Insights

/PRNewswire/ -- On September 9, 2022, BMS announced the FDA approval of Sotyktu for moderate-to-severe plaque psoriasis (PsO), making it the first selective...

Related Keywords

Abbvie Humira ,Abbvie Rinvoq ,Cibinqo Incyte Opzelura ,Scott Upham ,Eli Lilly Olumiant ,Amgen Otezla ,Gianna Melendez ,Linkedin ,Twitter ,Corporate Communications ,Dynamix ,Spherix Network ,Launch Dynamix ,Eli Lilly ,Realtime Dynamix ,Plaque Psoriasis ,Global Insights ,Spherix Global Insights ,Global Insights Contacts ,Dermatology Franchise ,